Loading...
NPI 1659351484 · East Syracuse, NY · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Richard Cherny is a hematology & oncology physician provider located in East Syracuse, New York. This profile covers 114 Medicare and 6 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Richard Cherny |
| Address | 5008 Brittonfield Pkwy |
| City | East Syracuse |
| State | NY |
| ZIP | 13057 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | January 18, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $6.3M |
| Medicaid | $8.5K |
This provider’s billing is overwhelmingly Medicare-driven: total Medicare revenue is $6.3M versus total Medicaid revenue of $8.5K, making Medicaid economically negligible compared with Medicare. The scale disparity indicates the practice is effectively a Medicare-focused operation rather than a mixed-payer practice on these datasets.
Revenue concentration on Medicare is high and centered on oncology biologics: the precomputed top 3 Medicare codes account for 57.1% of this provider's total Medicare revenue, led by J9299, J9271, and J9144. Those top drugs (nivolumab, pembrolizumab, daratumumab) are high-cost, infusion-based immunotherapies and monoclonal antibodies, indicating the service line is an infusion-oriented hematology/oncology practice that bills buy-and-bill oncology agents.
J9299 (nivolumab) is a clear national outlier for this provider: it shows 54.2K claims, $1.3M revenue (21.6% of Medicare revenue) and ranks #8 of 505 providers nationally (99th percentile; extreme outlier, far above typical national volume for this code). Complementary procedure volumes also show outsized activity — 96413 ranks #42 of 7514 providers nationally (99th percentile; extreme outlier) — together these patterns indicate unusually large infusion throughput relative to national peers.
Several other high-revenue Medicare codes place the provider well above typical national volumes but not uniformly dominant: J9144 (daratumumab) generates $916.6K and ranks #32 of 615 (94th percentile; notably above typical national volume), while J9271 (pembrolizumab) contributes $1.2M and ranks #145 of 1841 (92th percentile; typical, unremarkable volume). In short, the provider is a major dispenser of certain targeted oncology agents (nivolumab and daratumumab) and a strong but more typical distributor of others like pembrolizumab.
Procedure-level measures reinforce high infusion activity: standalone chemotherapy administration and related infusion codes such as 96413 ($113.2K, 1.9% of Medicare revenue; ranks #42 of 7514, 99th percentile; extreme outlier) and 96375 ($24.4K; ranks in the 99th percentile; extreme outlier) appear at very high percentiles, consistent with a high-volume outpatient infusion practice. These elevated procedure ranks, combined with high biologic drug volumes, suggest the provider operates significant infusion capacity and handles complex regimens rather than primarily outpatient E&M visits.
The provider’s Medicaid footprint is tiny and highly concentrated: the top 3 Medicaid codes account for 92.4% of Medicaid revenue, with 96413 alone representing 71.0% of Medicaid revenue (275 claims, $6.1K) yet ranking only #116 of 196 in-state (41st percentile; typical, unremarkable volume). This indicates the practice does not capture meaningful Medicaid market share statewide and that its Medicaid billing is focused on chemotherapy administration rather than a broader mix of services.
Tenure is long-standing: the NPI was enumerated on 2006-01-18 (~20 years ago), which supports the interpretation that these billing patterns reflect an established hematology/oncology practice rather than a new entrant. Established enumeration combined with concentrated Medicare specialty volume suggests stable referral and infusion infrastructure that has been operating for many years.
Competitive implications for payers: given the heavy Medicare concentration in a small set of high-cost oncology agents (top 3 Medicare codes = 57.1% of Medicare revenue) and several codes flagged as extreme outliers or notably above typical volumes, payers and network managers should treat this provider as a high-impact outpatient infusion site for oncology drugs. Management levers for payers could include focused utilization oversight, site-of-care and buy-and-bill contracting reviews, and attention to coding consistency for the handful of drugs and administration codes driving most spend.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
114 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9299 | Injection, nivolumab, 1 mg | 54,210 | $20 | $1.3M |
| J9271 | Injection, pembrolizumab, 1 mg | 28,410 | $40 | $1.2M |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase‑fihj | 24,120 | $40 | $916.6K |
| J9022 | Injection, atezolizumab, 10 mg | 6,550 | $60 | $419.3K |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 10,620 | $40 | $403.6K |
| J1930 | Injection, lanreotide, 1 mg | 9,120 | $40 | $401.3K |
| J9173 | Injection, durvalumab, 10 mg | 4,970 | $60 | $308K |
| J0897 | Injection, denosumab, 1 mg | 11,100 | $20 | $199.8K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 1,140 | $100 | $113.2K |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | 3,700 | $30 | $96.1K |
Showing 1–10 of 114
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 114 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
114 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 2 | 60 | 9,900 | $40 | $505.5K |
| J9144 | 3 | 20 | 10,440 | $40 | $499.4K |
| J9299 | 1 | 10 | 14,670 | $20 | $438.2K |
| J9173 | 2 | 10 | 5,380 | $60 | $334.5K |
| J9022 | 1 | 10 | 4,700 | $60 | $300.9K |
| J1930 | 1 | 10 | 3,840 | $40 | $241.5K |
| J1561 | 7 | 40 | 3,100 | $40 | $234.9K |
| J1449 | 1 | 10 | 3,700 | $30 | $95K |
| J0897 | 44 | 490 | 2,820 | $20 | $84.4K |
| Q5119 | 3 | 10 | 2,100 | $20 | $51.1K |
Showing 1–10 of 114
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
6 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 280 | $20 | $6K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 50 | $20 | $970 |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 40 | $20 | $860 |
| 96372 | A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician… | 190 | $1 | $370 |
| 96375 | Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the… | 90 | $1 | $280 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 20 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
6 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 116 | 200 | 630 | $150 | $338K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 15,397 | 19,110 | 360 | $70 | $321K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 12,428 | 16,550 | 220 | $90 | $186.8K |
| 96375 | Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the… | 225 | 250 | 2,570 | $10 | $53.3K |
| 96372 | A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician… | 812 | 1,420 | 300 | $20 | $38.8K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 329 | 360 | 560 | $1 | $1.3K |
Other providers in the same ZIP code as Richard Cherny, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Syracuse Endoscopy Associates, LLC | NY | Endoscopy Clinic/Center | $560.3K | $1.1M |
| K&a Radiologic Technology Services Inc | NY | Portable X-ray and/or Other Portable Diagnostic Imaging Supplier | $638.2K | $89.1K |
| Upstate Orthopedics Ambulatory Surgery Center LLC | NY | Ambulatory Surgical Clinic/Center | $402.5K | $83.6K |
| Benny Wong | NY | Hematology & Oncology Physician | $403.7K | $7.3K |
| Vinod Varki | NY | Hematology & Oncology Physician | $388.7K | $0 |
| Aref Agheli | NY | Hematology & Oncology Physician | $364.3K | $1.8K |
| Jeffrey Cizenski | NY | Dermatology Physician | $290.7K | $0 |
| Robert Sherman | NY | Orthopaedic Surgery Physician | $258.5K | $5K |
| Traian Anghel | NY | Clinical Cardiac Electrophysiology Physician | $256K | $190 |
| Hassan Shukri-mahmod | NY | Neurology Physician | $215.9K | $12.8K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.